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Background: The purpose of this study was to gather information about analgesic drug therapy 
in patients with chronic pain and perform cost estimates to guide future cost-effectiveness 
research in the area.
Methods: Data from patients aged 44 years and over suffering from any chronic condition and 
receiving regular analgesic drug therapy (for $6 months) who attended health care facilities 
within the area of Badalona during 2008 were collected in a retrospective study. Morbidity pro-
files were defined according to treatment setting (pain unit, hospital), World Health Organization 
analgesic step (1–2 versus 3), and a raw cost model based on resource use and work absenteeism 
was applied. Patients attending the pain unit or the hospital were considered undertreated if they 
were on step 1–2 analgesics. Multiple regression was used to compare costs between undertreated 
and non-undertreated patients among those attending the pain unit or the hospital.
Results: Only 410 of 18,157 patients ascertained (2.3%) were on step 3 analgesics. Their direct 
costs were greater than those of patients on step 1–2 analgesics, although the opposite was true 
regarding indirect costs. Of patients seen in the pain unit and in the hospital, 2.3% and 20.1%, 
respectively, were considered undertreated. Regression analyses revealed even greater costs in 
the subgroup of undertreated patients.
Conclusion: Step 3 analgesics are barely used. Up to one-fifth of patients may be undertreated, 
generating greater costs than those considered to be properly treated. Regression analyses did 
not clarify the proportion of their cost excess that was attributable to undertreatment.
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Introduction
According to the International Association of the Study of Pain, pain can be defined as 
a disagreeable sensorial and emotional sensation associated with real or potential tissue 
damage.1 Its duration can be classified as acute or chronic, although it is sometimes 
difficult to distinguish between the two in clinical practice, because pain often has 
an oscillating presentation, sometimes with pain-free periods.2 Acute pain is of short 
duration, often has an identifiable cause, and responds well to analgesics. In contrast, 
chronic pain is often independent of the original cause, is usually more difficult 
to treat, and can itself be considered as an illness. Chronic pain is a public health 
problem worldwide.3–5 Pain is a multidimensional problem influenced by biological, 
psychological, and social factors. Chronic pain will become more prevalent in the 
future, owing to increased life expectancy. Currently, the prevalence of chronic pain 
ranges from 10.1% to 55.2%, depending on the population studied and the study design, 
although current evidence suggests that approximately 20% of the adult population 
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(aged over 18 years) in developing countries suffers from 
chronic pain.6–10 Chronic pain can be considered as the third 
most important health problem in our setting, after cardio-
vascular disease and cancer, and has important economic 
repercussions, not only associated with medical, surgical 
and pharmaceutical costs, but also with work absenteeism, 
disability, and diminished quality of life.11–13
The World Health Organization analgesic ladder, based 
on the severity of pain (step 1, mild pain; step 2, moderate 
pain; and step 3, intense pain), reserves treatment with   opiates 
for moderate-severe pain.14–16 This therapeutic approach 
has been shown to be very effective in treating cancer pain. 
  However, the use of opiates for noncancer pain is contro-
versial, because of concerns about their efficacy and safety, 
and the possibility of addiction.17,18 There is some evidence to 
suggest that chronic pain tends to go undertreated. Important 
contributing factors include: insufficient information about 
pain physiology; low sensitivity and specificity of the 
diagnosis; a lack of treatment guidelines reached by consensus; 
poor understanding of the medicinal products used, mainly 
of their mechanisms of action; reluctance to use certain 
pharmacological agents (especially opiates); and/or concern 
about the development of side effects, interactions, tolerance, 
or addiction (safety of the medication).19,20 In the light of 
this situation, more controlled clinical trials are required to 
establish a role for opiate therapy in the treatment of chronic 
pain and to identify criteria that can be used to select patients 
and treatment algorithms. This study is considered to be of 
relevance, owing to the insufficient epidemiological studies 
in patients with chronic pain and of the associated costs 
(economic analyses). This article presents the results of a 
retrospective observational study that compiled systematic 
sociosanitary, clinical, and health care data related to pain 
treatment in patients with chronic illnesses in an urban area 
of Spain. The aim was to determine patterns of analgesic drug 
therapy in routine clinical practice, the resources used, and 
the associated costs, with the aim of guiding future studies 
of cost-effectiveness and determining cost-related factors in 
the Spanish population with chronic pain.
Materials and methods
Design and study population
A retrospective multicenter study was carried out by exam-
ining the medical records (computer databases) of patients 
followed in an outpatient setting and in hospital. The study 
population comprised patients from six primary care centers, 
ie, Apenins-Montigala, Morera-Pomar, Montgat-Tiana, Nova 
Lloreda, La Riera, and Marti-Julia, managed by   Badalona 
Serveis Assistencials SA. Information was obtained about 
the resources available in the two reference hospitals, ie, 
Hospital Municipal de Badalona and Hospital Germans Trías 
i Pujol (specialist care). The patients assigned to these centers 
mainly come from urban areas, have middle-low economic 
status, and mostly work in industry.
Inclusion and exclusion criteria
All patients attending the center for health care between 
  January and December 2008 were recruited into the study 
if they presented with the following characteristics: age 
45 years or older; diagnosed with an illness that had produced 
chronic pain for at least 6 months before the start of the 
study; inclusion in the program to receive chronic medical 
prescriptions (with records of the daily dose, time interval, 
and duration of each treatment administered); and use of more 
than five boxes of analgesics during the study period. Patients 
were excluded if they had been referred to other primary care 
centers, had died, or moved out of the area.
Study groups in relation to use  
of analgesic medications
Data about medicinal analgesic products were obtained 
from prescriptions of dispensed products collected from the 
pharmacies, according to the procedure for monitoring phar-
maceutical prescriptions of CatSalut. Patients were selected 
if they regularly used nonopiate analgesics, nonsteroidal anti-
inflammatory drugs, or weak or strong opiates according to 
the Anatomical Therapeutic Chemical classification system.21 
Finally, two study groups were established according to the 
World Health Organization analgesic ladder, ie, patients in 
step 1–2 (taking nonopiates and weak opiates), and patients 
in step 3 (treated with strong opiates). Details of the active 
ingredients of the drugs taken are shown in Table 1.
Sociodemographic and comorbidity data
The main study variables were: age (continuous and 
by intervals) and gender, and the patient’s personal 
background obtained from the CIAP-222 component 7 of 
illness and health problems: arterial hypertension (K86, 
K87), diabetes mellitus (T89, T90), dyslipidemia (T93), 
obesity (T82), smoking (P17), alcoholism (P15, P16), all 
types of organ failure (cardiac, hepatic and renal), ischemic 
heart disease (K74, K76, K75), stroke (K90, K91, K93), 
chronic obstructive pulmonary disease (R95, chronic airway 
obstruction), bronchial asthma (R96), dementia or memory 
disorders (P70, P20), neurological diseases [Parkinson’s 
disease (N87),   epilepsy (N88), multiple sclerosis (N86) 
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and other neurological diseases (N99)]; and depressive 
syndrome (P76).
As a variable of general comorbidity for each patient 
attended in primary care, the Charlson Comorbidity Index23 
was used to give an approximation of the severity of the 
patient’s condition, as well as the individual casuistic index, 
obtained from the adjusted clinical groups (ACG), and used 
to classify patients according to case-mix resource uti  lization. 
Mapping of the Clinical Information Access Portal was 
carried out according to international disease classification 
(ICD-9-CM). This was done by a working group compris-
ing five experts (a documentalist, two clinicians, and two 
technical advisers). Different criteria were followed depend-
ing on whether no relationship (of one to none), a univocal 
relationship (of one to one), or a multiple relationship 
(from one to several) was established among the codes. The 
Grouper ACG® case-mix system algorithm comprises a 
series of consecutive steps to obtain 106 mutually exclusive 
ACG groups, one for each patient.24,25 The ACG procedure 
provides resource utilization bands, such that each patient 
can be grouped in relation to their overall comorbidity into 
one of five mutually exclusive categories, ie, healthy users 
or ones with a very low morbidity, low morbidity, moderate 
morbidity, high morbidity, and very high morbidity.
Major morbidity categories
Following the recommendations of the Spanish Pain 
Association (Sociedad Española del Dolor), patients were 
classified into four specific groups or categories: malignant 
neoplasms (this includes any type of malignant or suspected 
neoplasm); neuropathic pain (direct lesion of the nervous 
system, including painful mononeuropathies [post-
traumatic, compressed nerve or radicular neuralgias], painful 
polyneuropathies, neuropathic pain by deafferentiation 
[eg, postherpetic neuralgia, amputation-induced neuromas, 
phantom limbs], and complex regional pain syndrome); 
musculoskeletal alterations (produced by dysfunction or 
pathology of components of the musculoskeletal system, 
including arthropathies [degenerative, inflammatory, 
crystalline deposits], alteration of soft tissues, bone 
diseases, and connective tissue disorders); and other chronic 
alterations. One patient could be included in several of these 
categories at the same time.
Estimation of efficacy
Given that there are no direct measures of efficacy, efficacy 
was estimated by considering five indicator measures, ie, 
treatment in a pain unit, specific analgesic treatment admin-
istered in a hospital, mean number of analgesics (nonopiate) 
Table 1 Distribution of different active ingredients included in the study according to therapeutic groups and classification of the 
World Health organization analgesic ladder
WHO ladder ATC Active ingredient Boxes % RRP %
Stage type 1 N02BE01 Paracetamol 67,211 37.8% 204,215.94 14.1%
M01AE01 Ibuprofen 26,612 15.0% 126,017.51 8.7%
N02BB02 Sodium metamizol 9198 5.2% 22,764.70 1.6%
M01AB05 Diclofenac 7715 4.3% 21,905.62 1.5%
M01AE17 Dexketoprofen 7498 4.2% 50,342.20 3.5%
M01AB16 Aceclofenac 5864 3.3% 46,906.17 3.2%
M01AE02 Naproxen 3303 1.9% 21,230.60 1.5%
N03AX16 Pregabalin 3274 1.8% 192,731.56 13.3%
N03AX12 Gabapentin 2947 1.7% 121,063.44 8.3%
M01AB01 indomethacin 2660 1.5% 7347.14 0.5%
M01AC06 Meloxicam 2494 1.4% 17,595.79 1.2%
M01AH01 Celecoxib 1426 0.8% 52,961.64 3.6%
Other (NSAiD analgesics) 8688 4.9% 125,412.62 8.6%
Stage type 2 N02AX52 Tramadol (combinations) 9934 5.6% 61,292.78 4.2%
N02AX02 Tramadol 8271 4.7% 151,615.23 10.4%
N02BE51 Paracetamol (combinations) 3957 2.2% 9600.97 0.7%
N02AA59 Codeine (combinations) 1690 1.0% 4849.84 0.3%
N02BA51 Acetyl salicylic acid (combined) 646 0.4% 1630.41 0.1%
Stage type 3 N02AB03 Fentanyl 2857 1.6% 160,003.15 11.0%
N02AE01 Buprenorphine 816 0.5% 38,037.71 2.6%
N02AA01 Morphine 586 0.3% 10,176.38 0.7%
N02AA05 Oxycodone 194 0.1% 3524.15 0.2%
Total 177,841 100.0% 1,451,225.55 100.0%
Abbreviations: WHO, World Health Organization; ATC, Guidelines for ATC classification; NSAID, nonsteroidal anti-inflammatory drug; RRP, recommended retail price.
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per patient, and mean number of days of hospital stay per 
patient. Moreover, the patients treated in a hospital or pain 
unit were considered to be undertreated if they fulfilled either 
of the first two criteria but were not on stage 3 analgesics. 
In spite of the fact that this is a speculative definition, the 
authors consider that, in the absence of direct measures of 
efficacy, it can be considered to be accurate, particularly 
taking into account that a recent epidemiological study in 
Spain on the treatment of chronic noncancer pain reported 
that more than 60% of patients were on step 3 analgesia 
(personal communication). In the present study, we would 
expect this proportion to be even higher, considering that we 
also included cancer patients.
Use of resources and models of costs
Direct health costs were considered to be those related to 
health care activity (eg, medical visits, days of hospital stay, 
emergencies, orders of diagnostic/therapeutic tests) and car-
ried out by health care professionals. Non-health care-related 
or indirect costs were those related to lost work productivity 
(number of absentees and days of absenteeism). The design of 
the cost system was defined by taking into account the char-
acteristics of the organizations and the degree of development 
of the information systems available. The product unit upon 
which the final calculation was based during the study period 
was the one the patient attended and the cost was expressed as 
mean cost per patient (cost/unit). The different study concepts 
and their economic analyses are shown in detail in Table 2 
(corresponding to data from 2008). The different fees were 
obtained from analytical accountancy data from each center, 
except for the cost of medication and days of absenteeism. 
Medical prescriptions (acute, chronic, or on demand) were 
quantified according to the recommended retail price per 
box at the time of prescription. Days of absenteeism or loss 
of productivity were considered as non-health care (indirect) 
costs. The cost was quantified in relation to the minimum 
interprofessional salary (sourced from Instituto Nacional de 
Estadística [INE]). In accordance with Spanish recommenda-
tions, the study protocol was approved by the Committee of 
Ethics of Clinical Research of the Foundation Gol and Gurina. 
All patients gave consent for their data to be used.
Confidentiality of data and statistical 
analysis
As a previous step to the analysis, especially before study-
ing the information source corresponding to patients’ com-
puterized clinical records, the data were carefully checked, 
observing their frequency distributions and possible errors in 
their recording or encoding. The confidentiality of data was 
respected according to the Organic Law on Data Protection 
(15/1999, of December 13). A descriptive univariate statisti-
cal analysis was conducted with mean values, standard errors/
deviations, and confidence intervals (CI) of 95%. The nor-
mality of the distribution was verified by the Kolmogorov–
Smirnov test. For bivariate analysis, Student’s t-test, analysis 
of variance, and Chi-square and Pearson’s linear correlation 
tests were used. The corrected comparison of undertreated 
patients with the rest of the patients treated in the pain unit 
or hospital was conducted according to the recommendations 
of Thompson and Barber,26 by a multiple linear regression 
analysis (using a stepwise procedure, covariates of age and 
gender, and Charlson Comorbidity Index). A logistic regres-
sion was carried out to determine the association between 
comorbidities and use of strong opiates (enter procedure 
and Wald statistics). SPSSWIN software (v 17; SPSS Inc, 
Chicago, IL) was used to establish statistical significance 
at P , 0.05.
Results
From an initial selection of 45,929 individuals aged over 
44 years assigned to and regularly attending six centers, 
a total of 18,157 patients were selected. The estimated preva-
lence of patients taking regular treatment for chronic pain was 
39.5% (95% CI: 39.1–39.9). By study group, 17,747 (97.7%) 
patients were in step 1–2 of treatment and 410 (2.3%) in step 3 
(P , 0.001). The mean age of the patients was 66.2 years and 
63.7% were women. The proportion taking opiate analgesia 
was 24.4% (n = 4427, 95% CI: 23.8–25.0).
Table 3 shows the general characteristics of the series, the 
associated comorbidities, and measures associated with the 
Table 2 Unit costs of health care resources and productivity 
losses from absenteeism
Health care resources and non-health  
resources
Unit costs (€)
Medical visits
  Visit to GP 22.74
  Visit to emergency service 115.23
  Hospitalization (one day) 314.61
  Specialist medical care (referral) 102.36
Additional tests
  Laboratory tests 21.86
  Conventional x-ray 18.14
  Diagnostic/therapeutic tests 36.45
Pharmaceutical prescription RRP
Work productivity
  Cost per day of absenteeism 54.65
Note: Source of health care data: authors’ analytical accounts.
Abbreviations: GP, general practitioner; RRP, recommended retail price.
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ef  ficacy in relation to treatment type. The s  ubjects treated with 
step 3 analgesia were of a higher mean age (70.5 years versus 66.1 
years; P , 0.001), and a larger proportion of these were women 
(74.9% versus 63.4%; P , 0.001). These subjects presented a 
greater overall comorbidity in episodes/patient (10.6 versus 7.6; 
P , 0.001) and Charlson index (1.3 versus 0.7; P , 0.001). 
In the corrected regression model, patients in step 3 pre-
sented a greater similarity in relation to cardiovascular 
events, odds ratio (OR): 1.9 (95% CI: 1.1–3.3), depressive 
syndrome, OR: 1.8 (95% CI: 1.5–2.3), female gender, OR: 
1.7 (95% CI: 1.3–2.1), and arterial hypertension, OR: 1.3 
(95% CI: 1.1–1.6, P , 0.031). The intake of strong opiates 
Table 3 General characteristics of the series studied and measures related to efficacy in analgesic stages
Study groups: analgesic step 
subjects, %
Type 1–2 
17,747 (97.7%)
Type 3 
410 (2.3%)
Total 
18,157 (100.0%)
P value
Sociodemographic characteristics
Mean age, years 66.1 ± 11.3 70.5 ± 11.6 66.2 ± 11.3 ,0.001
  45–54 years 17.7% 11.2% 17.5%  
  55–64 years 29.5% 19.3% 29.3%  
  65–74 years 26.8% 28.0% 26.8%  
  75–84 years 20.7% 31.2% 21.0%  
 . 84 years 5.3% 10.2% 5.4% ,0.001
Gender (women) 63.4% 74.9% 63.7% ,0.001
General comorbidity        
Mean RUB/patient 3.0 ± 0.6 3.3 ± 0.6 3.0 ± 0.6 ,0.001
1 2.2% 0.0% 2.2%  
2 10.5% 4.1% 10.4%  
3 75.0% 66.3% 74.8%  
4 10.7% 23.9% 11.0%  
5 1.5% 5.6% 1.6% ,0.001
Mean of episodes/patient 7.6 ± 3.9 10.6 ± 5.2 7.7 ± 3.9 ,0.001
Mean Charlson index 0.7 ± 1.1 1.3 ± 1.4 0.7 ± 1.1 ,0.001
Associated comorbidities        
Arterial hypertension 50.6% 63.9% 50.9% ,0.001
Diabetes mellitus 20.1% 31.0% 20.4% ,0.001
Dyslipemia 45.3% 44.5% 45.2% NS
Obesity 17.8% 18.7% 17.9% NS
Active smokers 13.2% 10.3% 13.2% NS
Alcoholism 2.0% 1.5% 1.9% NS
ischemic heart disease 8.4% 14.0% 8.5% ,0.001
Stroke 9.6% 14.7% 9.7% ,0.001
Cardiovascular events 16.4% 27.3% 16.7% ,0.001
Organic insufficiencies 10.2% 17.2% 10.3% ,0.001
Bronchial asthma 5.1% 7.1% 5.1% 0.039
COPD 6.5% 8.4% 6.6% NS
Neuropathies 1.1% 2.9% 1.1% 0.002
Dementia (all types) 2.0% 2.5% 2.0% NS
Depressive syndrome 20.7% 34.4% 21.0% ,0.001
Major diagnostic categories        
Cancer pain 9.0% 19.0% 9.2% ,0.001
Neuropathic pain 29.7% 44.4% 30.0% ,0.001
Musculoskeletal pain 81.2% 78.5% 81.2% NS
Other alterations 11.3% 6.8% 11.2% 0.003
Measures related to efficacy        
Patients visiting pain units 2.0% 18.3% 2.4% ,0.001
Hospital admissions 17.8% 36.6% 18.2% ,0.001
Mean of active ingredients/patient 2.3 ± 1.3 4.5 ± 1.4 2.3 ± 1.4 ,0.001
Mean of opiates/patient 0.2 ± 0.4 1.5 ± 0.5 0.3 ± 0.5 ,0.001
Mean of hospital stays/patient 1.2 ± 5.5 2.0 ± 8.5 1.4 ± 6.4 ,0.001
Abbreviations: RUB, resource utilization bands; COPD, chronic obstructive pulmonary disease; NS, not statistically significant.
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was associated with cancer pain (OR: 1.6, 95% CI: 1.3–2.0). 
An estimated 2.3% of patients received step 3 analgesics, 
re  presenting 4.7%, 3.3%, 2.2%, and 1.4% of patients with 
cancer pain, neuropathic pain, musculoskeletal pain, and pain 
of other origin, respectively.
The association between efficacy of treatment in the 
major diagnostic categories and study groups (analgesic 
treatment) is shown in Table 4. It is noteworthy that, using 
these indicators, on average 2.3% and 20.1% of patients 
did not receive adequate analgesia (undertreated) with step 
1–2 analgesics when referred to the pain unit or admitted to 
hospital, respectively.
Table 5 shows the cost model (average/unit) of the series 
studied in the different analgesic steps. Patients taking step 
3 analgesics required more resources, as recorded on the 
prescriptions for analgesics and greater direct health care 
costs. However, the indirect costs were lower in these patients. 
The total cost of health care in these patients amounted to 
EUR 50.1 million, of which 89.9% corresponded to direct 
health care costs and 10.1% to indirect health care costs. 
The av  erage/unit of total costs (health-related, non-health-
related) in subjects on step 3 of the analgesic ladder was 
€5764.1 versus €2686.9 (P , 0.001).
Multiple linear regression models adjusted for patients 
treated in the pain unit and in the hospital are shown in 
Table 6. Undertreatment was associated with an increase 
in total costs compared with patients on step 3 treatment. 
However, owing to the minimal contribution of the variables 
included in the adjusted analyses to the total variables, the 
increase in costs could have other causes not recorded here, 
such as the more complicated clinical conditions.
Discussion
In spite of the abundant information available on chronic 
pain, there are very few studies relating morbidity profiles to 
the treatments and resources utilized and the associated costs. 
This circumstance, together with the systematization of the 
database studied, makes this research of conceptual interest. 
The results suggest that step 3 analgesia is rarely used, and 
this is associated with an increase in direct costs. Nonetheless, 
without an appropriate standardization of the methodologies 
in relation to the patients’ characteristics, and the number and 
measurement of the variables studied, the results obtained 
must be interpreted carefully and their external validity must 
be considered with caution.27 An important contribution of 
this work was adjustment of morbidity on the basis of a case-
mix resource utilization such as ACG.24,25
The general results of our study show a prevalence of 
patients receiving regular treatment for chronic pain of around 
39.5%, with a utilization of opiates in 24.4%. In spite of the 
variability among the studies reviewed, these percentages are 
slightly higher than those reported in studies of the general 
population.6–9 This could be due to the fact that the patients 
studied in this work were aged over 44 years, and also due 
to the inclusion of patients with cancer pain. Nevertheless, 
the association of chronic pain with a larger proportion of 
osteoarticular problems (especially in the elderly, who have 
greater comorbidity), female gender, and mental illness, is 
similar to findings published previously.5,6 Regarding the 
analgesic regime in these patients, there appears to be an 
underutilization of step 3 analgesics, suggesting that many 
patients could be undertreated. There is also a clear underuse 
of opiates in most of the studies reviewed.16,17 Even doctors 
experienced at treating chronic pain show a reluctance to 
use opiates to treat severe noncancer pain. Our findings 
agree with those of Nicholson et al who suggest a need 
for doctors to receive better training in the use of opiates 
for analgesia.29 Inadequate pain relief can have important 
Table  4  Relationship  between  efficacy  (pain  unit,  hospital 
treatment) and major diagnostic categories relative to the study 
groups (analgesic treatment)
Characteristic 
pain unit
Present 
n = 439
Absent 
n = 17,772
Step type 1–2 (n, %)
Cancer pain 25 (1.6) 1577 (98.4)
Neuropathic pain 220 (4.2) 5058 (95.8)
Musculoskeletal pain 308 (2.2) 14,155 (97.9)
Other alterations 23 (1.1) 1990 (98.9)
Mean, % 2.3 97.7
Step type 3 (n, %)
Cancer pain 6 (7.6) 73 (92.4)
Neuropathic pain 41 (22.4) 142 (77.6)
Musculoskeletal pain 63 (19.3) 263 (80.7)
Other alterations 7 (25.0) 21 (75.0)
Mean, % 18.6 81.4
Hospital treatment n = 3322 n = 14,889
Step type 1–2 (n, %)
Cancer pain 460 (28.7) 1142 (71.3)
Neuropathic pain 915 (17.3) 4363 (82.7)
Musculoskeletal pain 2565 (17.7) 11,898 (82.3)
Other alterations 332 (16.5) 1681 (83.5)
Mean, % 20.1 80.0
Step type 3 (n, %)
Cancer pain 34 (43.0) 45 (57.0)
Neuropathic pain 49 (26.8) 134 (73.2)
Musculoskeletal pain 120 (36.8) 206 (63.2)
Other alterations 11 (39.3) 17 (60.7)
Mean, % 36.5 63.5
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  depressive and emotional effects, causing suffering for 
patients and their relatives and also an increase in the use of 
health resources.12,20
Since there is no direct measure of efficacy available, 
a patient was considered to be undertreated in a pain unit 
and/or when receiving analgesic treatment in a hospital if 
they did not receive any step 3 analgesics. This corresponded 
to 20.1% of patients in our study, and only 2.3% received 
strong opiates. It is difficult to draw comparisons with our 
results, although the use of strong opiates is similar to that 
described in the literature. A review by Galvez30 describes 
how only 5% of patients in Europe received treatment with 
strong opiates, although there was some variability among 
countries. These percentages were higher (11%–13%) in 
Ireland, the UK, and Denmark, whereas this was only 1% in 
Spain. Nonetheless, we must take into consideration that the 
use of opiates to treat chronic noncancer pain has not been 
well established, because there are still only a few systematic 
reviews and meta-analyses for this type of long-term pain.30–33 
In clinical practice, treatment with opiates is conditioned 
by ethical, cultural, and legal considerations, because it 
can produce tolerance, adverse reactions, and physical 
dependence, leading to abstinence syndrome.19 However, 
effective treatment of pain and the control of side effects is 
an attainable goal in most patients with chronic pain. Latest 
reports support effective analgesia, especially in severe pain, 
where opiates play a more prominent role, particularly with 
controlled-release formulations of morphine, oxycodone, and 
transdermal patches of fentanyl and buprenorphine, which 
have less pronounced side effects.30 Patient response to these 
drugs may be variable, so treatment should be personalized. 
The mechanisms involved in irregular analgesic response and 
the appearance of side effects are not well known. Recently, 
a set of guidelines has been devised with the purpose of 
optimizing analgesic treatment with opiates. Briefly, these 
recommend adjusting the analgesic treatment to the intensity 
of pain, using the most appropriate route of administration 
for each patient, and monitoring the patient and dose with 
regular check-ups.30,34
In the regression model, it is important to note that in 
routine clinical practice “undertreatment” was ass  ociated 
Table 5 Costs model (average/unit) of the series studied according to the different analgesic stages
Study groups 
subjects, %
Type 1–2 
17,747 (97.7%)
Type 3 
410 (2.3%)
Total 
18,157 (100.0%)
P value
Cost in primary care 1942.5 ± 1294.9 3719.6 ± 2280.1 1982.7 ± 1351.2 ,0.001
Visits to GP   273.7 ± 216.6   459.5 ± 301.8   277.9 ± 220.6 ,0.001
Clinical tests   121.9 ± 97.2   137.8 ± 114.2   122.3 ± 97.6 ,0.001
X-rays   88.3 ± 90.1   103.3 ± 103.5   88.7 ± 90.4 ,0.001
Additional tests   40.7 ± 63.3   60.9 ± 91.2   41.2 ± 64.2 ,0.001
Referral to specialists   627.3 ± 504.4   992.7 ± 896.7   635.6 ± 519.4 ,0.001
Pharmaceutical prescription   790.6 ± 866.4 1965.4 ± 1566.9   817.1 ± 905.2 ,0.001
Cost in specialist care   464.9 ± 1864.9 1786.0 ± 4255.3   494.7 ± 1961.0 ,0.001
Hospital stay   405.0 ± 1834.8 1649.0 ± 4225.9   433.1 ± 1930.6 ,0.001
Emergencies   59.8 ± 117.7   137.0 ± 202.6   61.6 ± 120.8 ,0.001
Total health care costs 2407.4 ± 2436.2 5505.6 ± 5046.4 2477.4 ± 2566.5 ,0.001
Non-health care costs (days absenteeism)   279.5 ± 1423.6   258.5 ± 1578.4   279.0 ± 1427.2 NS
Total cost (health care and non-health care) 2686.9 ± 2794.3 5764.1 ± 5265.2 2756.4 ± 2909.5 ,0.001
Note: Values expressed in Euros.
Abbreviations: GP, general practitioner; NS, not significant.
Table  6  Multiple  linear  regression  model  with  association 
between variable undertreatment and costs
Variables of equation Coefficient 95% CI
Dependent: total costs (€) [R2 = 0.09]
Constant* 3507 2626–4386
Age, years 10 -3–23
Gender, man versus woman -148 -440–143
Charlson index* 975 868–1082
Undertreatment (yes versus no) 383 -69–836
Dependent: total costs (€) [R2 = 0.09]
Constant* 4.07 3697–4442
Age, years -50 -55–44
Gender, man versus woman -196 -319–73
Charlson index* -29 -74–16
Undertreatment (yes versus no) -138 -329–54
Dependent: total costs (€) [R2 = 0.15]
Constant* -563 -1365–239
Age, years 60 48–71
Gender, man versus woman 48 -218–314
Charlson index* 1,004 906–1101
Undertreatment (yes versus no) 521 109–934
Note: *Statistical significance (the confidence interval does not include 0).
Abbreviations: CI, confidence interval; R2, coefficient of determination of the model.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Treatment profiles and costs of chronic painClinicoEconomics and Outcomes Research 2012:4
with costs even greater than in patients on step 3 of 
t  reatment. This could possibly be due to a selection bias, 
because the patients attended/selected who were being 
treated in the pain unit and/or hospital could, in general, 
present with more clinical complications than the others, 
and higher costs may be due largely to greater morbidity or 
severity. Nonetheless, since this comparison was made in 
the subgroup of patients treated in the pain unit or hospital, 
and, by definition, undertreated patients received step 3 
analgesics (that have higher direct costs than the rest of 
the sample), this would suggest that the higher costs in the 
present study correspond to undertreated patients. A more 
appropriate, or better, treatment of these patients could 
reduce costs because an improvement in pain intensity, 
quality of life, or functionality would result directly in less 
use of health care resources.12,34,35
Possible limitations of this study lie in its limited 
geographical distribution, categorization of the disease 
(chronic pain), a possible bias in the classification of 
patients (analgesic step) and, especially, the lack of any 
direct measures of efficacy in the information system 
developed. Chronic pain conditions will most often pos-
sess many overlapping features between neuropathic, 
nociceptive, and even cancer pain syndromes. Categoriz-
ing chronic pain into distinct groupings may meet adminis-
trative requirements, but may not be functional in clinical 
practice. In addition, the World Health Organization ladder 
is based on subjective evaluation and a physician’s clinical 
trial for the treatment of individual patients, so that could 
be considered by itself as a slightly objective parameter to 
assess the intensity of pain. In this study, we considered 
the World Health Organization analgesic ladder as a single 
indicator or isolated under treatment, as has always been 
taken into account in the quantitative administration of 
various drugs with the use of the expertise of pain. There-
fore, this article reflects the limitations of the retrospective 
studies themselves; including an underrecording of the 
illness, its duration in time, or the possible doses of medi-
cation prescribed. Moreover, the variables that probably 
make an important contribution to establishing the costs 
present a clear dispersion among the regression models 
studied. In spite of these limitations, the results presented 
in this study still reflect a good approach to the pattern of 
use of analgesics in chronic pain. Future research must 
focus on cost/efficacy studies, for which direct measures 
of efficacy are required, and more controlled clinical trials 
to establish the role of opiate treatment in chronic pain of 
noncancer origin.
Conclusion
The results of this study indicate that step 3 analgesics are 
underused, since up to a fifth of patients may be undertreated 
and present greater associated direct costs. However, regres-
sion analysis did not identify the proportion of excess cost 
that was attributable to undertreatment.
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